Request Information
About TheraSeed®
Straight Talk
Facts
The Procedure
At a Glance
Advantages Over Surgery
All Seeds Not Equal
Treatment Decision
What Experts Say
Ask Your Doctor
Compare Treatments
About Prostate Cancer
Family & Friends
What Experts Say about Brachytherapy and TheraSeed® Treatment
 Print | E-mail

Independent clinical studies verify the effectiveness of brachytherapy with the TheraSeed® device. Here’s what experts have concluded:

BRACHYTHERAPY LONG-TERM RESULTS
• Brachytherapy with Pd-103 produces a biochemical control rate better than or equal to surgery; 12-year research proves superior efficacy for high- and intermediate-risk patients. (Sharkey, et. al., Brachytherapy, 2005)
• Up to 12 years after treatment, brachytherapy produces long-term survival rates similar to radical prostatectomy and external beam radiation therapy. (Potters, et. al., Journal of Urology, 2005)
BRACHYTHERAPY EFFECTIVENESS
• Brachytherapy can be an effective treatment for patients regardless of risk factor or age, and severe urinary or rectal complications are rare. (Merrick, et. al., The Journal of Urology, 2003)
• Pd-103 treatment has a remarkably high cure rate for higher risk prostate cancer patients. (Dattoli, et. al., Cancer, 2003)
• Nine years following TheraSeed® treatment, 83.5% of patients with a broad spectrum of Gleason scores were free of prostate cancer. (Blasko, et. al., International Journal of Radiation Oncology Biology – Physics, 2000)
BRACHYTHERAPY COMPARISON TO OTHER TREATMENTS
• Cure rates are similar for localized prostate cancer patients treated with permanent seed implants, surgery, high-dose external beam radiotherapy and combined permanent seed implants with external beam radiotherapy. (Kupelian, et. al., International Journal of Radiation Oncology Biology – Physics. 2004)
• Patients with the best profile for a good surgical outcome also are the best candidates for brachytherapy. (Peschel, et. al., The Lancet Oncology, 2003)
BRACHYTHERAPY COMPLICATIONS COMPARED TO SURGERY
• Brachytherapy produces a cure rate as high as surgery, and has a lower rate of complications, such as incontinence and impotence. (Sharkey, et. al., Current Urology Reports, 2002)
PD-103 SEEDS COMPARED TO I-125 SEEDS
• Patients treated with Pd-103 recover from radiation irritation sooner than I-125 patients. (Wallner, et. al., The Cancer Journal, 2002)
• Patients receiving palladium-based seeds experience significantly fewer complications than those receiving iodine-based seeds. (Peschel, et. al., Radiation Oncology Investigations, 1999)
OF NOTE
• Surgery frequently doesn’t remove all cancer cells. Forty-seven percent of men undergoing radical prostatectomy had cancer cells remaining in the body following surgery for localized prostate cancer. (Frank D. Gilliland, M.D., et. al., Journal of Urology, 1999)